GE molecular diagnostics
This article was originally published in The Gray Sheet
Executive Summary
General Electric reaffirms its interest in supplementing imaging with in vitro diagnostics Oct. 1 with a three-year agreement with Eli Lilly to develop molecular assays that help target cancer therapies. The multiplexed tissue tests being developed at GE Healthcare and GE Global Research aim to identify protein and gene signatures to predict whether Eli Lilly's drugs will be effective. The collaboration follows the collapse of GE's planned buyout of part of Abbott's diagnostics business for $8 billion in July (1"The Gray Sheet" July 16, 2007, p. 3)
You may also be interested in...
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.